Latest Regulatory Filings News

Emperor Energy's Environmental Plan for the Judith-2 Well has passed NOPSEMA's completeness check and is now open for public comment, marking a key regulatory milestone on the path to drilling in mid-2026.

Donaco International Limited has postponed its Scheme of Arrangement timetable amid extended legal and valuation reviews, while revealing a new 10% VAT gaming tax liability in Cambodia effective from January 2025.

DMC Mining Limited has extended the closing date for its public share offer to August 2025 due to delays in securing exploration licences for its key Guinea projects. The company plans further regulatory updates to accommodate these changes.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

Helia Group’s 1Q25 APRA lodgement reveals robust growth in gross written premiums and statutory net profit, while the company voices concerns over proposed government changes to the Home Guarantee Scheme that could reshape its market dynamics.

Clime Investment Management has been appointed lead manager for a significant US public offer fund by Sphinx Investments, with initial allocations of $183 million AUD pending SEC approval. The move marks a strategic expansion into the US market, complemented by new wholesale offerings and a partnership with a Dallas-based equities manager.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Bio-Gene Technology Limited has been awarded two significant grants totaling A$3 million by the US Department of Defense, validating its innovative insecticide technologies Flavocide® and Qcide®. The company is advancing regulatory filings and scaling production to target both military and civilian markets.

Argenica Therapeutics has completed patient dosing in its Phase 2 trial of ARG-007 for acute ischaemic stroke, with topline data expected in Q3 2025. The company also plans to submit its Investigational New Drug application and Fast Track request to the FDA imminently.

Medallion Metals has secured a positive EPBC Referral decision for its Ravensthorpe Gold Project, marking a crucial milestone in its sulphide development strategy. The company aims to submit additional environmental data by March 2025, targeting final approval by Q3 2025 while progressing drilling and financing.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.